NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 138 filers reported holding NEVRO CORP in Q3 2023. The put-call ratio across all filers is 2.46 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,337,213 | -24.6% | 4,231,905 | -0.3% | 0.00% | -33.3% |
| Q2 2023 | $107,844,909 | -31.7% | 4,242,522 | -2.8% | 0.00% | -25.0% |
| Q1 2023 | $157,808,739 | -2.9% | 4,365,387 | +6.3% | 0.00% | 0.0% |
| Q4 2022 | $162,571,859 | -3.7% | 4,105,350 | +13.4% | 0.00% | -20.0% |
| Q3 2022 | $168,743,000 | +8.1% | 3,621,085 | +1.7% | 0.01% | +25.0% |
| Q2 2022 | $156,070,000 | -33.7% | 3,560,796 | +9.5% | 0.00% | -33.3% |
| Q1 2022 | $235,246,000 | -8.9% | 3,252,411 | +2.1% | 0.01% | 0.0% |
| Q4 2021 | $258,223,000 | -31.5% | 3,185,178 | -1.7% | 0.01% | -33.3% |
| Q3 2021 | $376,980,000 | -32.1% | 3,239,214 | -3.3% | 0.01% | -35.7% |
| Q2 2021 | $555,249,000 | +20.5% | 3,349,111 | +1.4% | 0.01% | +16.7% |
| Q1 2021 | $460,826,000 | -14.1% | 3,303,411 | +6.6% | 0.01% | -25.0% |
| Q4 2020 | $536,651,000 | +30.4% | 3,100,236 | +5.0% | 0.02% | +14.3% |
| Q3 2020 | $411,419,000 | +12.7% | 2,953,467 | -3.4% | 0.01% | +7.7% |
| Q2 2020 | $365,177,000 | +29.9% | 3,056,650 | +8.7% | 0.01% | +8.3% |
| Q1 2020 | $281,104,000 | -12.9% | 2,811,607 | +2.4% | 0.01% | +9.1% |
| Q4 2019 | $322,778,000 | +37.2% | 2,746,109 | +0.3% | 0.01% | +22.2% |
| Q3 2019 | $235,265,000 | +35.9% | 2,736,583 | +2.5% | 0.01% | +28.6% |
| Q2 2019 | $173,140,000 | +7.8% | 2,670,677 | +4.0% | 0.01% | +16.7% |
| Q1 2019 | $160,557,000 | +58.2% | 2,568,494 | -1.6% | 0.01% | +20.0% |
| Q4 2018 | $101,486,000 | -29.3% | 2,609,571 | +3.6% | 0.01% | -16.7% |
| Q3 2018 | $143,558,000 | -23.8% | 2,518,566 | +6.7% | 0.01% | -25.0% |
| Q2 2018 | $188,424,000 | -0.2% | 2,359,740 | +8.4% | 0.01% | 0.0% |
| Q1 2018 | $188,719,000 | +27.6% | 2,177,448 | +1.6% | 0.01% | +33.3% |
| Q4 2017 | $147,943,000 | -22.1% | 2,142,872 | +2.6% | 0.01% | -33.3% |
| Q3 2017 | $189,795,000 | +29.2% | 2,088,425 | +5.8% | 0.01% | +28.6% |
| Q2 2017 | $146,862,000 | -19.0% | 1,973,146 | +2.0% | 0.01% | -22.2% |
| Q1 2017 | $181,271,000 | +35.9% | 1,934,593 | +5.4% | 0.01% | +28.6% |
| Q4 2016 | $133,407,000 | -19.9% | 1,836,038 | +15.1% | 0.01% | -30.0% |
| Q3 2016 | $166,480,000 | +54.4% | 1,594,794 | +9.1% | 0.01% | +42.9% |
| Q2 2016 | $107,847,000 | +38.0% | 1,462,128 | +5.3% | 0.01% | +40.0% |
| Q1 2016 | $78,125,000 | +2.1% | 1,388,631 | +22.5% | 0.01% | 0.0% |
| Q4 2015 | $76,510,000 | +55.8% | 1,133,317 | +7.1% | 0.01% | +150.0% |
| Q3 2015 | $49,110,000 | -3.2% | 1,058,631 | +12.2% | 0.00% | -33.3% |
| Q2 2015 | $50,731,000 | +144.9% | 943,829 | +118.4% | 0.00% | +200.0% |
| Q1 2015 | $20,712,000 | +52.4% | 432,135 | +23.0% | 0.00% | 0.0% |
| Q4 2014 | $13,590,000 | – | 351,452 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |